Toshiya Abe1, Chiho Koi1, Shiro Kohi1, Ki-Byung Song1, Koji Tamura1, Anne Macgregor-Das1, Naoki Kitaoka1, Miguel Chuidian1, Madeline Ford1, Mohamad Dbouk1, Michael Borges1, Jin He2, Richard Burkhart2, Christopher L Wolfgang2, Alison P Klein3, James R Eshleman3, Ralph H Hruban3, Marcia Irene Canto4, Michael Goggins5. 1. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland. 2. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland. 3. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland. 4. Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland. 5. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland. Electronic address: mgoggins@jhmi.edu.
Abstract
BACKGROUND & AIMS: Levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA-125) in blood are used as markers to determine the response of patients with cancer to therapy, but are not used to identify patients with pancreatic cancer. METHODS: We obtained blood samples from 504 patients undergoing pancreatic surveillance from 2002 through 2018 who did not develop pancreatic cancer and measured levels of the tumor markers CA19-9, CEA, CA-125, and thrombospondin-2. Single-nucleotide polymorphisms (SNPs) in FUT3, FUT2, ABO, and GAL3ST2 that have been associated with levels of tumor markers were used to establish SNP-defined ranges for each tumor marker. We also tested the association between additional SNPs (in FUT6, MUC16, B3GNT3, FAM3B, and THBS2) with levels of tumor markers. To calculate the diagnostic specificity of each SNP-defined range, we assigned the patients under surveillance into training and validation sets. After determining the SNP-defined ranges, we determined the sensitivity of SNP-adjusted tests for the tumor markers, measuring levels in blood samples from 245 patients who underwent resection for pancreatic ductal adenocarcinoma (PDAC) from 2010 through 2017. RESULTS: A level of CA19-9 that identified patients with PDAC with 99% specificity had 52.7% sensitivity. When we set the cut-off levels of CA19-9 based on each SNP, the test for CA19-9 identified patients with PDAC with 60.8% sensitivity and 98.8% specificity. Among patients with FUT3 alleles that encode a functional protein, levels of CA19-9 greater than the SNP-determined cut-off values identified 66.4% of patients with PDAC, with 99.3% specificity. In the validation set, levels of CEA varied among patients with vs without SNP in FUT2, by blood group, and among smokers vs nonsmokers; levels of CA-125 varied among patients with vs without the SNP in GAL3ST2. The use of the SNPs to define the ranges of CEA and CA-125 did not significantly increase the diagnostic accuracy of the assays for these proteins. Combining data on levels of CA19-9 and CEA, CA19-9 and CA-125, or CA19-9 and thrombospondin-2 increased the sensitivity of detection of PDAC, but slightly reduced specificity. CONCLUSIONS: Including information on SNPs associated with levels of CA19-9, CEA, and CA-125 can improve the diagnostic accuracy of assays for these tumor markers in the identification of patients with PDAC. Clinicaltrials.gov no: NCT02000089.
BACKGROUND & AIMS: Levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA-125) in blood are used as markers to determine the response of patients with cancer to therapy, but are not used to identify patients with pancreatic cancer. METHODS: We obtained blood samples from 504 patients undergoing pancreatic surveillance from 2002 through 2018 who did not develop pancreatic cancer and measured levels of the tumor markers CA19-9, CEA, CA-125, and thrombospondin-2. Single-nucleotide polymorphisms (SNPs) in FUT3, FUT2, ABO, and GAL3ST2 that have been associated with levels of tumor markers were used to establish SNP-defined ranges for each tumor marker. We also tested the association between additional SNPs (in FUT6, MUC16, B3GNT3, FAM3B, and THBS2) with levels of tumor markers. To calculate the diagnostic specificity of each SNP-defined range, we assigned the patients under surveillance into training and validation sets. After determining the SNP-defined ranges, we determined the sensitivity of SNP-adjusted tests for the tumor markers, measuring levels in blood samples from 245 patients who underwent resection for pancreatic ductal adenocarcinoma (PDAC) from 2010 through 2017. RESULTS: A level of CA19-9 that identified patients with PDAC with 99% specificity had 52.7% sensitivity. When we set the cut-off levels of CA19-9 based on each SNP, the test for CA19-9 identified patients with PDAC with 60.8% sensitivity and 98.8% specificity. Among patients with FUT3 alleles that encode a functional protein, levels of CA19-9 greater than the SNP-determined cut-off values identified 66.4% of patients with PDAC, with 99.3% specificity. In the validation set, levels of CEA varied among patients with vs without SNP in FUT2, by blood group, and among smokers vs nonsmokers; levels of CA-125 varied among patients with vs without the SNP in GAL3ST2. The use of the SNPs to define the ranges of CEA and CA-125 did not significantly increase the diagnostic accuracy of the assays for these proteins. Combining data on levels of CA19-9 and CEA, CA19-9 and CA-125, or CA19-9 and thrombospondin-2 increased the sensitivity of detection of PDAC, but slightly reduced specificity. CONCLUSIONS: Including information on SNPs associated with levels of CA19-9, CEA, and CA-125 can improve the diagnostic accuracy of assays for these tumor markers in the identification of patients with PDAC. Clinicaltrials.gov no: NCT02000089.
Authors: Elizabeth C Verna; Caroline Hwang; Peter D Stevens; Heidrun Rotterdam; Stavros N Stavropoulos; Carolyn D Sy; Martin A Prince; Wendy K Chung; Robert L Fine; John A Chabot; Harold Frucht Journal: Clin Cancer Res Date: 2010-09-28 Impact factor: 12.531
Authors: H Narimatsu; H Iwasaki; F Nakayama; Y Ikehara; T Kudo; S Nishihara; K Sugano; H Okura; S Fujita; S Hirohashi Journal: Cancer Res Date: 1998-02-01 Impact factor: 12.701
Authors: Toshiya Abe; Amanda L Blackford; Koji Tamura; Madeline Ford; Patrick McCormick; Miguel Chuidian; Jose Alejandro Almario; Michael Borges; Anne Marie Lennon; Eun Ji Shin; Alison P Klein; Ralph H Hruban; Marcia I Canto; Michael Goggins Journal: J Clin Oncol Date: 2019-03-18 Impact factor: 44.544
Authors: Marcia Irene Canto; Tossapol Kerdsirichairat; Charles J Yeo; Ralph H Hruban; Eun Ji Shin; Jose Alejandro Almario; Amanda Blackford; Madeline Ford; Alison P Klein; Ammar A Javed; Anne Marie Lennon; Atif Zaheer; Ihab R Kamel; Elliot K Fishman; Richard Burkhart; Jin He; Martin Makary; Matthew J Weiss; Richard D Schulick; Michael G Goggins; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2019-06-13 Impact factor: 3.452
Authors: Ingrid C A W Konings; Femme Harinck; Jan-Werner Poley; Cora M Aalfs; Anja van Rens; Nanda C Krak; Anja Wagner; C Yung Nio; Rolf H Sijmons; Hendrik M van Dullemen; Frank P Vleggaar; Margreet G E M Ausems; Paul Fockens; Jeanin E van Hooft; Marco J Bruno Journal: Pancreas Date: 2017-01 Impact factor: 3.327
Authors: Andreas Wannhoff; Johannes Roksund Hov; Trine Folseraas; Christian Rupp; Kilian Friedrich; Jarl Andreas Anmarkrud; Karl Heinz Weiss; Peter Sauer; Peter Schirmacher; Kirsten Muri Boberg; Wolfgang Stremmel; Tom Hemming Karlsen; Daniel Nils Gotthardt Journal: J Hepatol Date: 2013-08-16 Impact factor: 25.083
Authors: Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Mohamad Dbouk; Bryson W Katona; Randall E Brand; Amitabh Chak; Sapna Syngal; James J Farrell; Fay Kastrinos; Elena M Stoffel; Amanda L Blackford; Anil K Rustgi; Beth Dudley; Linda S Lee; Ankit Chhoda; Richard Kwon; Gregory G Ginsberg; Alison P Klein; Ihab Kamel; Ralph H Hruban; Jin He; Eun Ji Shin; Anne Marie Lennon; Marcia Irene Canto; Michael Goggins Journal: J Clin Oncol Date: 2022-06-15 Impact factor: 50.717